“The fast growing demand for Comparability of Biologics needs creative steps and business models. Protagen and VELA are internationally renowned and well-established contract research labs for complete characterization of Biopharmaceuticals and Biosimilars, and both companies belong to the leading providers of ICH-compliant analytical services. Our customers will benefit from this alliance through more efficient project work and study design“, states Dr. Markus Fido, CEO of VELA Laboratories.
“The technology portfolio and the exceptional expertise of VELA in the area of bioassays for potency determination of therapeutic antibodies, growth factors and protein hormones, will synergistically complement the experience and competences of Protagen. Our customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio“, comments Dr. Stefan Müllner, CEO of Protagen AG.
“The technology portfolio and the exceptional expertise of VELA in the area of bioassays for potency determination of therapeutic antibodies, growth factors and protein hormones, will synergistically complement the experience and competences of Protagen. Our customers in the pharmaceutical and biotech sector as well as CROs and CMOs will profit from this alliance through the direct access to a comprehensive service portfolio“, comments Dr. Stefan Müllner, CEO of Protagen AG.
Companies in this article
![Alison Bryant, senior consultant at Antea Group and communications director for the Healthcare Plastics Recycling Council (HPRC), addressed the crowd at the[PACK]out.](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2024/05/Alison_Bryant.6644005a513b0.png?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
